MicroGenDX

Unlock the power of Next-Generation Sequencing with MicroGenDX and never let cultures keep you down. Our innovative DNA sequencing analysis process can identify over 50,000 microbial species accurately and quickly to provide health professionals with all the information they need for confident treatment decisions. Explore this groundbreaking technology today! Click on our link https://loom.ly/BFCDCM8 to learn more about what we do!

Excited to share my first review article, published this week by Infectious Disease in Clinical Practice with Ravina Kullar, PharmD, and infectious disease colleagues. My contribution focused on explaining a few core concepts in microbial next-generation sequencing (#NGS) as is commercially available for infectious disease diagnostics. I’ve gotten many questions since starting with #MicroGenDX that boil down to understanding what our test is, how our application of NGS differs from research applications of sequencing, and what our results tell you. While the review focused a bit on PJI and orthopedic infection, for my part I’ve addressed several recurring broad topics and questions such as: -?????????What is NGS and how does it work? -?????????What types of NGS laboratory tests are available right now to clinicians? -?????????What are the qualifications to look for in a diagnostic lab offering NGS and how is NGS regulated? -?????????NGS is extremely sensitive, so how is the false positive rate controlled? -?????????Could the bacteria found by NGS be from dead organisms (or non-viable DNA)? -?????????What are the best marker gene targets for microbial profiling? -?????????Adopting NGS into clinical practice has a cost, but can it be cost effective? Read our full review here for answers to these questions and more -> https://lnkd.in/gR-hbeVw

Hello Friends of MicroGenDX, We need your help. The IDSA has requested public comments for the 2025 guidelines for the management and treatment of complicated UTIs but there is no mention of NGS (https://loom.ly/1fRAIjM). Your comments could make a difference. MicroGenDX has processed more than 200 thousand urine samples, and we have helped thousands of patients who suffered from UTIs. However, the insurance carriers still refuse to cover our test. When refusing coverage to patients the insurance industry often references that there is no mention of NGS in the UTI guidelines (in either AUA or IDSA). The result is the financial burden is placed on the patients when their insurance refuses to cover our test. MicroGenDX has priced our test to patients at $249, less than the cost of a culture when you add aerobic, anaerobic and fungal plates together. Insurance companies such as Aetna, Humana, Cigna, and the Blues will have to cover our test for UTIs when we have the IDSA and the AUA Guidelines supporting NGS. We are not asking to replace culture, we are asking that NGS be a diagnostic option when the patient has met the clinical criteria for infection, yet the cultures are negative or provide no diagnostic value. Forcing the physician to only rely on culture just adds to the Antimicrobial Resistance (AMR) problem as patients are prescribed one antibiotic after another. Denying the use of our test because of fear of providers treating non-pathogens is not an argument when the planned IDSA guidelines call for use of empiric broad-spectrum antibiotics. Additionally, MicroGenDX has added a column to our report showing which species are known pathogens, commensals, or not classified either way (unknown) in order to help providers target the necessary organisms. The 2024 IDSA Guidelines for the Microbiology Laboratory (https://loom.ly/jXP7yTM) support NGS for a range of infections from joint infections to Endocarditis and many more. Evidence clearly shows we can help a patient with an infected knee and soft tissue infections, why should a patient suffering from a UTI that has not responded to standard of care, also not have access to our service? Please help us help patients by getting NGS acknowledged by the ISDA for use in CUTI paving the way for better coverage by insurance companies and wider availability from healthcare providers. Here is the link to the survey on the IDSA website https://loom.ly/1fRAIjM Alternatively, you can email your comments directly to: [email protected] with the subject line: “2025 IDSA Guidelines for the management and treatment of complicated UTIs” The survey will ask you to leave a comment on a specific section of the guidelines. Please select “Executive Summary” And leave a comment suggesting that the guidelines take into consideration utilizing NGS testing to diagnose infecting organisms. Thank you! Rick Martin, CEO MicroGenDX #uti #cuti #guidelines #IDSA # NGS # MicroGenDX

Releasing Rapid H5: Fast, Accurate H5 Flu A Testing MicroGenDX is proud to launch Rapid H5, a PCR test to detect H5 Influenza A, including the current avian flu strain, H5N1, directly from patient samples. With results within 24-48 hours of receipt by our lab, this test helps healthcare providers meet the CDC’s January 2025 recommendation to subtype all Influenza A positive cases for H5 within 24 hours, to support better patient care and preparedness for public health and hospitals. Rapid H5 offers: ? One test, no two-step workflow ? Compatible with UTM, VTM, eSwab? ? Fast, reliable molecular detection As H5N1 spreads in animal populations and poses a risk of human-to-human spread, the need for rapid and precise diagnostics is increasingly essential. The MicroGenDX Rapid H5 test will equip healthcare professionals with the tools to enable timely detection and treatment. At MicroGenDX, we are committed to advancing molecular diagnostics, delivering reliable testing solutions that strengthen public health preparedness. Contact your MicroGenDX Representative for more information or order at https://loom.ly/UuAds4w #MicroGenDX #FluA #H5N1 #PCR #MolecularDiagnostics #PublicHealth

An 86-year-old patient faced major problems including infection, necrosis, and hematoma after a skin cancer surgery. His situation was grim and regular treatments were not helping. A MicroGenDX NGS test was ordered and uncovered the infection's cause: Fusobacterium nucleatum It's a dangerous bacterium that can spread throughout the body, wreaking havoc if left untreated. -causing gum disease -infecting the heart and brain -endangering pregnancies -promoting colon cancer The presence of this bacteria prevented the wound from healing. With the proper insight from MicroGenDX results, his care team treated him with the right antibiotics and healed him within weeks – showing precision medicine at work! Could NGS make a difference for you? Learn more here: https://microgendx.com/ #Healthcare #MicroGenDX #Medicine #PatientStories

Modernize Your Practice with Redefined Pathogen Detection Today’s dynamic medical landscape necessitates moving on from traditional culture methods to detect pathogens as culture falls short of modern standards. Studies reveal that culture testing can miss up to 40% of orthopedic infection cases, putting many patients at risk of improper treatment due to hidden pathogens. As expectations for personalized medicine grow, it’s time to reconsider how we diagnose infections. MicroGenDX’s Next-Gen DNA Sequencing (NGS) testing kits present a novel, DNA-based approach to microbe detection, setting a new standard in diagnostic sensitivity, specificity, and speed: ? Higher sensitivity: NGS identifies pathogens with superior 99.2% accuracy, so you can pinpoint the exact cause of an infection with confidence. ? Improved specificity: With greater, DNA-level specificity, NGS minimizes the risk of false positives due to culture contamination, leading to targeted treatments that address the underlying pathogens. ? Faster, Comprehensive results: While traditional cultures can take days or weeks, NGS delivers a holistic microbial profile of the infection, in a fraction of the time, drawing upon an expansive library of over 57,000 species. MicroGenDX is empowering orthopedic surgeons and the wider physician community to move beyond culture, an outdated 19th-century method and align with the precision and accuracy that today’s patient care requires. Incorporating NGS into your practice leads to faster, more reliable diagnostics and improved patient outcomes. Upgrade your practice with MicroGenDX’s leading-edge NGS kits to bring 21st-century diagnostics to Medicine. It’s to modernize infection management. Learn More: https://loom.ly/WdQj5xg #Diagnostics #Infection #Orthopedic #PrecisionMedicine #NGS #Pathogens #Healthcare #MicroGenDX

Missed our webinar, "Optimizing Antifungal Therapy: Two-Step Rapid Fungal Diagnostic by PCR/NGS"? You can still catch it on-demand! Gain insights on rapid fungal diagnostics, antifungal stewardship, and real-world implementation strategies. Sign up on Labroots to access the full recording: https://loom.ly/V6KF-bA #WebinarOnDemand #FungalDiagnostics #AntifungalTherapy #Microbiology #MicroGenDX

How a Breakthrough Test Helped End Three Years of Chronic Infection A 63-year-old man from Wisconsin struggled with painful infectious head cysts for three years. Despite multiple doctor visits, medications, and procedures, no treatment provided long-term relief. When referred to Angela Rhode, a wound care nurse practitioner in Wisconsin, she used MicroGenDX’s Next-Generation DNA Sequencing (NGS) to identify the exact bacteria and fungi causing his infections. With this information, she prescribed a targeted treatment plan. In just three weeks, his infections were fully healed, ending years of frustration. This success shows the power of NGS testing to find answers for chronic infections when other methods fail. Learn more: https://loom.ly/gieX79w #ChronicInfections #NGS #Success #WoundCare #AdvancedDiagnostics #MicroGenDX #Infection #PrecisionMedicine #Health #HealingJourney #TargetedTherapy #InnovativeHealthcare #PatientCare #MedicalInnovation

Attention Microbiologists and Infectious Disease Professionals: Join us for a game-changing webinar! "Optimizing Antifungal Therapy: Two-Step Rapid Fungal Diagnostic by PCR/NGS" Learn how to revolutionize fungal diagnostics and improve patient care with cutting-edge tools and strategies. Date: January 30, 2025 Time: 8:00 AM (PST) | 11:00 AM (EST) | 5:00 PM (CET) What you’ll gain: Insight into PCR/NGS technology for fungal identification in 24-48 hours with 99% precision. The impact of rapid diagnostics on antifungal stewardship and patient outcomes. Real-world strategies for integrating these tools into clinical practice. Featured speakers: Dr. Jose Alexander, Director of Microbiology Laboratories, AdventHealth Orlando Dr. Nicholas Sanford, Assistant Lab Director & VP of Medical Affairs, MicroGenDX Stay at the forefront of fungal diagnostics and antifungal therapy optimization. Register today: https://loom.ly/V6KF-bA #Webinar #Microbiology #FungalDiagnostics #AntifungalTherapy #PCR #NGS #MicroGenDX

65 y.o. male w/ index TKA performed 2 years ago at outside facility. Developed pain, stiffness & loss of function immediately. Patient reports that aspiration was performed sometime ago that was "negative". Physical exam notable for 20-50 motion & gross atrophy of the quadriceps in particular. Radiographs showed marginal lucencies below the baseplate. Open biopsy performed w/ cultures & NGS (Microgen DX). Culture negative, but discovered bacteria via NGS, Cutibacterium Acnes. So, a 2 year head start on us! You can see from pics of the knee pre-op, the gross swelling present & the gross atrophy. Patient required a significant debridement. All dense scar, diseased edematous synovium & bone debridement (Mostly Type 2 Osteo modest amount Type 4). The LINK "Hinge in a Box", Endo Model knee necessary due to ligament & peri-capsular debridement. Post-op ROM 0-90 and hoping for more! #UndiagnosedPJI #BigTimeDebridement #MicrogenDXngs #HingeInaBox